IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.
About IPO Scanner
IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.
Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.
Details of client bank account
For any query / feedback / clarifications, email at
[email protected].
Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.
© 2026 IPO Scanner. All rights reserved.
Want to stay updated?Subscribe to our newsletter
Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics is a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others.
Our product candidates consist of antimicrobials targeting acute and chronic infectious diseases, which are delivered locally to the site of infection.
As of December 2025, we hold 68 issued and 29 pending patent applications for our products and technologies, with coverage in major pharmaceutical markets.
Ticker, listing venue and issuer profile
Pricing terms and IPO milestones
Real-time price and trading activity
USD · NASDAQ:NASDAQ:LABT
Key valuation ratios and metrics
Balance sheet strength and liquidity
Margins and return on capital
Historical financial performance
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-05-14 | $2.83 | $2.83 | $1.92 | $1.96 | $1.96 | -0.87 | 406,000 |
| 2026-05-13 | $3.15 | $3.21 | $2.95 | $2.95 | $2.95 | -0.20 | 109,800 |
| 2026-05-12 | $3.12 | $3.32 | $3.12 | $3.22 | $3.22 | +0.10 | 224,600 |
| 2026-05-11 | $3.14 | $3.18 | $3.11 | $3.16 | $3.16 | +0.02 | 149,100 |
| 2026-05-08 | $3.25 | $3.26 | $2.93 | $3.10 | $3.10 | -0.15 | 152,000 |
| 2026-05-07 | $3.17 | $3.40 | $3.17 | $3.30 | $3.30 | +0.13 | 367,700 |
| 2026-05-06 | $2.93 | $3.28 | $2.93 | $3.13 | $3.13 | +0.20 | 287,800 |
| 2026-05-05 | $2.91 | $3.25 | $2.91 | $3.10 | $3.10 | +0.19 | 398,700 |
| 2026-05-04 | $2.77 | $3.30 | $2.77 | $3.26 | $3.26 | +0.49 | 820,600 |
| 2026-05-01 | $4.22 | $4.61 | $3.14 | $3.43 | $3.43 | -0.79 | 46,400,900 |
| 2026-04-30 | $3.51 | $3.55 | $2.58 | $2.66 | $2.66 | -0.85 | 307,000 |
| 2026-04-29 | $3.45 | $3.86 | $3.32 | $3.59 | $3.59 | +0.14 | 170,000 |
| 2026-04-28 | $3.63 | $4.04 | $3.14 | $3.89 | $3.89 | +0.26 | 276,800 |
| 2026-04-27 | $5.75 | $6.06 | $3.60 | $3.66 | $3.66 | -2.09 | 580,800 |
| 2026-04-24 | $8.65 | $9.40 | $7.01 | $7.35 | $7.35 | -1.30 | 5,211,100 |
| 2026-04-23 | $8.00 | $9.82 | $5.75 | $8.65 | $8.65 | +0.65 | 137,600 |
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| 424B4 | May 14, 2026 | Prospectus |
| EFFECT | May 13, 2026 | Notice of Effectiveness |
| S-1 | May 1, 2026 | General form for registration of securities under the Securities Act of 1933 |
| 424B3 | Apr 30, 2026 | Prospectus |
| 8-K | Apr 28, 2026 | Current Report |
| 424B4 | Apr 23, 2026 | Prospectus |
| CERT | Apr 22, 2026 | Certification by an exchange approving securities for listing |
| EFFECT | Apr 17, 2026 | Notice of Effectiveness |
| 8-A12B | Apr 17, 2026 | Registration of securities |
| S-1/A | Apr 6, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
Contact and headquarters details
Key executives and officers
Doug Manion, M.D., FRCP (C)
Chairman of the Board
Kelvin Cooper, Ph.D.
Chief Executive Officer, SVP Research & Development, Director
Peter Ceccacci
Chief Financial Officer, VP Administration
Thomas Balzer, M.D., Ph.D.
Chief Medical Officer, SVP Clinical Development
Leonard J. DeRoma
Director

Shares
18.68M o/s · 4.69M offered
Listing Price
$8.00
Probable listing
Apr 23, 2026
Sector
Healthcare